Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease? @checkrare
Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?  @checkrare
Uploaded September 2026 | Updated November 2026, 3 days ago
This educational program, hosted by Dawn Laney, MS, CGC, CCRC, Genetic Counselor and Program Leader for the Lysosomal Storage Disease Center at Emory University, and Staci Kallish, DO, Associate Professor of Clinical Medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania, examines how best to respond to patients concerns about how their Fabry disease, and its comorbidities, are managed. This program features a dialogue between patients who express their unmet needs, while two renowned Fabry disease experts translate these challenges into actionable clinical strategies.

Topic covered in this video segment is how well the medical team works together and understands Fabry disease.

This educational program is a non-CME activity made possible by an unrestricted grant from Amicus Therapeutics

Faculty
Dawn Laney, MS, CGC, CCRC
Genetic Counselor, Division of Medical Genetics
Program Leader, Lysosomal Storage Disease Center
Emory University School of Medicine
Disclosures
Consulting agreements: Amicus Therapeutics, Chiesi, Sanofi
Member: North American and International Fabry Registry Boards

Staci Kallish, DO
Associate Professor of Clinical Medicine
Division of Translational Medicine and Human Genetics
Perelman School of Medicine, University of Pennsylvania
Disclosures
Research grants: ashibio, Astellas Pharma, , Amicus Therapeutics
Idorsia Therapeutics, Incyte , Ipsen, and Sanofi
Consulting: Amicus Therapeutics, Sanofi
Advisory board: Amicus Therapeutics, Intrabio, Sanofi
Speaking honoraria: Amicus Therapeutics, Astellas, Sanofi

Learning Objective
Upon completion of this program, participants will be able to:
• Orchestrate a cohesive, multidisciplinary team approach to care.
Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?Increased Dosing Interval of Mogamulizumab in Patients With CTCLThe Changing Myasthenia Gravis Treatment LandscapePatient Perspective: Diagnostic Journey With IgA NephropathyC3G and the Pediatric VALIANT StudyIMAAVY Approval for wAIHAFDA Approves Multiple Myeloma Drug;  FDA Denies Neuroendocrine Drug; Safety Concerns For Prader-W...FDA Approves Rare Disease Treatments as Huntington’s Gene Therapy AdvancesNew Rare Disease Center of Excellence and FDA Advances in Rare DiseaseEXPAND Study on Ultra-Rare Cholestatic Liver DiseaseThe Role of Rusfertide in Decreasing Phlebotomies in Patients With Polycythemia VeraFDA Approves New Narcolepsy Treatment
CheckRare |

Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER